Şunu aradınız:: healthy subjects (İngilizce - Estonca)

healthy subjects
terved katsealused

in healthy subjects miglustat is rapidly absorbed.
tervetel uuringus osalejatel imendub miglustaat kiiresti.

healthy subjects were also included in clinical studies.
kliinilistes uuringutes osalesid ka terved isikud.

half life is approximately 50% shorter in healthy subjects.
tervetel inimestel on poolväärtusaeg umbes 50% võrra lühem.

this mode of administration was only studied in healthy subjects.
seda manustamisviisi on uuritud ainult tervetel isikutel.

apremilast was studied in young and elderly healthy subjects.
apremilasti uuriti noortel ja eakatel tervetel uuritavatel.

studies were conducted in healthy subjects unless otherwise noted.
uuringud viidi läbi tervete isikutega, kui ei ole teisiti märgitud.

as with healthy subjects, the half-life of pantoprazole is short.
sarnaselt tervete isikutega on pantoprasooli poolväärtusaeg lühike.

the pharmacokinetics of bosentan have mainly been documented in healthy subjects.
bosentaani farmakokineetikat on uuritud peamiselt tervetel indiviididel.

profiles following singles doses of effentora and otfc in healthy subjects
profiilid effentora ja otfc ühekordse mannustamise järgselt tervetel katsealustel

tho approximately equivalent with the target exposure observed in healthy subjects.
pe vabatahtlikel.

the cmax was similar between healthy subjects and patients with renal impairment.
tervete uuritavate ja neerukahjustusega patsientide cmax oli sarnane.

elbasvir pharmacokinetics are similar in healthy subjects and hcv-infected subjects.
elbasviiri farmakokineetika on sarnane tervetel isikutel ja hcv-infektsiooniga isikutel.

food had relatively modest effects on the pharmacokinetics of saxagliptin in healthy subjects.
toidul on suhteliselt tagasihoidlik toime saksagliptiini farmakokineetikale tervetel vabatahtlikel.

in haemodialysis patients, cmax was 41 % higher than that observed in healthy subjects.
hemodialüüsi patsientidel oli cmax 41 % kõrgem kui tervetel.

exposure to darunavir was higher in hiv-1 infected patients than in healthy subjects.
hiv-1-infektsiooniga patsientidel oli darunaviiri ekspositsioon suurem kui tervetel uuritavatel.

the absolute bioavailability of subcutaneous injectable epoetin alfa is approximately 20% in healthy subjects.
subkutaanselt süstitava alfaepoetiini absoluutne biosaadavus on tervetel uuritavatel ligikaudu 20%.

defitelio pharmacokinetic parameters after intravenous infusion of 6.25 mg/kg to healthy subjects.
defitelio farmakokineetilised näitajad tervetel vabatahtlikel pärast intravenoosset infusiooni annuses 6,25 mg kehakaalu kg kohta.

exposure to dolutegravir was generally similar between healthy subjects and hiv-1–infected subjects.
dolutegraviiri kontsentratsioon oli üldjuhul sarnane tervetel uuritavatel ja hiv-1 infektsiooniga isikutel.

the absolute bioavailability of cobimetinib was 45.9% (90% ci: 39.7%, 53.1%) in healthy subjects.
tervetel isikutel oli kobimetiniibi absoluutne biosaadavus 45,9% (95% ci: 39,7%, 53,1%).